Biophytis sets up Asia JV for BIO101 in Hong Kong

Biophytis S.A. has submitted the registration filing for its new joint venture in Hong Kong, Biophytis Biopharmaceutical Holding LTD, created with Asian partners including Ronghui Renhe Life Technology.

Rhea-AI Filing Summary

Biophytis S.A. has submitted the registration filing for its new joint venture in Hong Kong, Biophytis Biopharmaceutical Holding LTD, created with Asian partners including Ronghui Renhe Life Technology. The joint venture is designed to speed up development and commercialization of BIO101 for sarcopenia across Asian markets.

Biophytis will contribute patents and a license to develop and commercialize BIO101 in China, Japan and South Korea, while Asian partners will provide a total committed financing of $20 million, starting with an initial $3 million tranche. After the expected official registration and Closing, the venture plans to launch operations focused on preparing a Phase 3 clinical study of BIO101 in Asia, filing required regulatory applications, and building local teams.

Insights

Biotech & partnering analyst

Strategic Asia JV links BIO101 rights with $20M committed funding.

Biophytis is formalizing an Asia-focused joint venture in Hong Kong to advance BIO101 in sarcopenia. The company contributes patents and regional commercialization rights, while Asian partners provide a committed financing package, aligning scientific assets with local capital and market access.

The total committed financing of $20 million, with an initial $3 million tranche, is earmarked for clinical and regulatory development of BIO101 toward marketing authorization in Asia. This directly ties funding to late-stage plans, including a Phase 3 clinical study and associated regulatory submissions.

The filing states that official registration is expected within days, with Closing to follow and immediate operational launch thereafter. Execution will hinge on timely regulatory interactions and successful Phase 3 preparation in Asian markets, which future company communications and trial milestones are likely to clarify.

Key Figures

Total committed financing: $20 million Initial financing tranche: $3 million BIO101 development stage in sarcopenia: Phase 3 ready to start +2 more

5 metrics

Total committed financing $20 million Funding from Asian partners for BIO101 clinical and regulatory development in Asia

Initial financing tranche $3 million First payment of the total committed financing to the joint venture

BIO101 development stage in sarcopenia Phase 3 ready to start Lead indication for BIO101 in muscular diseases

BIO101 development stage in obesity Phase 2 ready to start Metabolic disorder indication for BIO101

Announcement time 7:00 a.m. CET Time of strategic update press release on June 2, 2026

Key Terms

joint venture, Phase 3 clinical study, marketing authorization, American Depositary Shares, +1 more

5 terms

joint venture financial

"submission of the registration filing for its joint venture in Hong Kong"

A joint venture is when two or more companies team up to work on a specific project or business idea, sharing both the risks and the rewards. It’s like friends starting a lemonade stand together—each contributes resources and they split the profits, making it easier to succeed than going alone.

Phase 3 clinical study medical

"preparing the Phase 3 clinical study of BIO101 in sarcopenia in Asia"

A phase 3 clinical study is a late-stage, large-scale test of a medical treatment in many patients to confirm how well it works and to monitor side effects before regulators consider approval. Think of it as a final dress rehearsal where the treatment is tested in diverse, real-world conditions to prove benefits outweigh risks. Investors watch these results because positive outcomes can clear the path to regulatory approval, sales, and major value changes.

marketing authorization regulatory

"support the clinical and regulatory development of BIO101 in sarcopenia through marketing authorization in Asia"

An official government approval that allows a drug, vaccine, or medical device to be sold and promoted in a specific country or region. Think of it as a safety and effectiveness passport issued after regulators review the product’s tests and manufacturing; for investors, receiving this authorization typically unlocks sales, revenue potential, and lower regulatory risk, while delays or denials can substantially affect a company’s value and timeline.

American Depositary Shares financial

"its ADS (American Depositary Shares) are listed on the OTC market"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

sarcopenia medical

"development and commercialization of BIO101 in sarcopenia across Asian markets"

FAQ

What did Biophytis (BPTSY) announce regarding its Hong Kong joint venture?

Biophytis announced it has submitted the registration filing for its Hong Kong joint venture, Biophytis Biopharmaceutical Holding LTD. This new entity focuses on developing and commercializing BIO101 for sarcopenia in Asian markets, in partnership with regional players including Ronghui Renhe Life Technology.

How much financing is committed to the Biophytis Hong Kong joint venture?

The joint venture’s Asian partners have committed $20 million of financing, with an initial payment of $3 million. This funding is intended to support BIO101’s clinical and regulatory development in sarcopenia, aiming to progress toward marketing authorization across Asian markets.

What will Biophytis contribute to the new Hong Kong joint venture?

Biophytis will contribute its patents and a license to develop and commercialize BIO101 in China, Japan and South Korea. These contributions give the joint venture the intellectual property and territorial rights needed to advance BIO101 into late-stage clinical development and market preparation in Asia.

What are the initial operational priorities for Biophytis’ Asian joint venture?

Once the transaction closes, the joint venture plans three priorities: prepare a Phase 3 clinical study of BIO101 in sarcopenia in Asia, submit required regulatory applications to initiate that study, and recruit specialized local teams. These steps aim to accelerate BIO101’s path toward potential approval.

Which partner is highlighted in Biophytis’ Hong Kong joint venture?

The joint venture includes Asian partners such as Ronghui Renhe Life Technology, described as a leading Chinese healthcare conglomerate. Ronghui Renhe operates across pharmaceuticals, medical devices, dermocosmetics and healthcare equipment, with strong manufacturing and distribution capabilities in China’s healthcare market.

What is BIO101 and why is it central to Biophytis’ Asian strategy?

BIO101 is Biophytis’ lead small-molecule drug candidate, 20-hydroxyecdysone, developed for muscular diseases like sarcopenia and metabolic disorders such as obesity. It is described as Phase 3 ready in sarcopenia, making it the cornerstone asset for the new Asian-focused joint venture strategy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 10:19 AM Learn about SEC filing dates

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: June 2, 2026

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On June 2, 2026, Biophytis S.A. issued a press release announcing the submission of the registration filing for its joint venture in Hong Kong. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated June 2, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: June 2, 2026	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer

Exhibit 99.1

BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE

REGISTRATION FILING SUBMITTED IN HONG KONG

Paris (France) and Cambridge (Massachusetts, U.S.), June 2, 2026, at 7:00 a.m CET. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily engaged in the manufacturing and distribution of healthcare products.

The joint-venture, named Biophytis Biopharmaceutical Holding LTD, is intended to accelerate the development and commercialization of BIO101 in sarcopenia across Asian markets. This milestone represents a significant and anticipated step in the implementation of Biophytis’ Asian development strategy, in line with the announcements made since the beginning of the year.

“The submission of this registration filing marks a key milestone in the execution of our Asian strategy. It reflects our commitment to establishing a long-term presence in this high-potential region. Biophytis Hong Kong will enable us, together with Ronghui Renhe, to strengthen our ability to make our therapeutic innovations accessible to a greater number of patients, particularly those affected by sarcopenia in China”, said Stanislas Veillet, CEO of Biophytis.

The official registration of the joint venture is expected within the coming days. In the following weeks, the respective contributions of the partners will be made, allowing completion of the transaction (the “Closing”). Biophytis SA will contribute to the joint venture its patents and a license to develop and commercialize BIO101 in China, Japan and South Korea, while the Asian partners will provide the first tranche of the total committed financing of $20 million, representing an initial payment of $3 million. This financing is intended to support the clinical and regulatory development of BIO101 in sarcopenia through marketing authorization in Asia.

The operational launch of the joint venture will take place immediately following the Closing, with a focus on three strategic priorities: preparing the Phase 3 clinical study of BIO101 in sarcopenia in Asia, submitting the regulatory applications required to initiate this study across the region, and recruiting dedicated local teams.

* * *

About Ronghui Renhe

Ronghui Renhe Group is a healthcare conglomerate headquartered in Shenzhen, China, bringing together several subsidiaries active in the pharmaceutical industry, medical devices, dermocosmetics and healthcare equipment sectors, with a significant presence in pharmaceutical distribution and healthcare product manufacturing.

About Biophytis

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age- related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Page 1 of 2

Biophytis Contact

Investor relations

investors@biophytis.com

Media relations

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50

Page 2 of 2

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 8.8 KB